98 results about "Cardiotoxicities" patented technology

The present invention provides assays and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. Said assays and kits are based on the finding that the interaction of astemizole with the HERG potassium channel can be exploited to predict cardiotoxicity of compounds during the development of new therapeutics and other agents.

The invention discloses an application of chiral chloroquine, hydroxychloroquine or pharmaceutically acceptable salts of the chiral chloroquine and hydroxychloroquine in preparation of drugs used forpreventing and / or treating coronavirus pneumonia by using a coronavirus key drug target 3CL hydrolase (Mpro) as an action target. The chiral chloroquine and hydroxychloroquine have high bonding strength with the Mpro causing inflammation of the lung and the like; the activity of the Mpro can be significantly inhibited; and the chiral chloroquine and hydroxychloroquine are indicated to have the effect of preventing and treating pneumonia caused by coronaviruses and be able to be used as anti-pneumonia drugs. Through evaluation on the inhibitory activity of an hERG potassium ion channel, the concentration at which the chloroquine, hydroxychloroquine and enantiomers of the chloroquine and hydroxychloroquine are likely to generate cardiotoxicity to the hERG potassium ion channel is provided. The chiral chloroquine and hydroxychloroquine are prepared through chiral high-performance liquid chromatography and chiral synthesis; S-configuration chloroquine, hydroxychloroquine or salts of the chloroquine and hydroxychloroquine can be selected as a drug independently, or form a pharmaceutical composition for treating diseases caused by the coronaviruses; and due to higher activity and low cardiotoxicity of the chloroquine, hydroxychloroquine or salts of the chloroquine and hydroxychloroquine, the administration dosage range is greatly widened.

The present invention discloses new rocaglaol derivatives and the use of rocaglaol derivatives to prevent or to limit the cardiotoxicity of an antineoplastic agent, in particular to prevent or to limit the apoptosis of cardiomyocytes induced by such agent.

The invention provides a method for evaluating various types of cardiotoxicity of tumor patients, and for the tumor patients, the evaluation factors related to the existing Meio cardiotoxicity scoring are limited, and the evaluation suggestions are general. According to the method provided by the invention, risk factors which have been researched and proved to have influences on cardiotoxicity are introduced, values are assigned to the risk factors according to the correlation degrees of the risk factors and various cardiotoxicity risks, an evaluation model is established by referring to a Meio scoring system, risk grading is carried out on the six types of cardiotoxicity, and corresponding evaluation suggestions are given; and according to the method, an existing evaluation system is expanded, the blank of domestic cardiotoxicity evaluation is filled, and reliable basis and suggestions are provided for clinicians to treat and follow up tumor patients.

Devices and methods for performing extracellular recording of cells, such as excitable cells, cardiomyocytes, and cardiomyocyte precursor cells is provided. An exemplary device includes a nonconductive substrate forming or provided as a base of one or more wells; a recording electrode positioned on the substrate within the well, wherein the recording electrode is accessible to cells when a cell sample is added to the device; and a reference electrode positioned within the well in a cell-free zone, the cell-free zone characterized as free from contact with cells when the cell sample is added to the device, thereby preventing contact between cells and the reference electrode.

The invention discloses a HER-2 humanized monoclonal antibody long-acting sustained-release preparation. The preparation comprises 2-50 wt% of an amphiphilic block copolymer mixture, 0.05-10 wt% of anHER-2 humanized monoclonal antibody and 40-88 wt% of a menstruum, and the storage modulus and the loss modulus of an amphiphilic block copolymer mixture aqueous solution have an intersection point at0-55 DEG C. By utilizing the dual action of the diffusion of the HER-2 humanized monoclonal antibody along with drugs and gel degradation, the stable and slow release is realized, so that tumor recurrence is inhibited, and the drug utilization rate is increased; within the dosage range of 0.05-10 wt%, the cardiotoxicity of the preparation can be remarkably reduced; and moreover, the release kinetics of the drugs can be effectively regulated and controlled by changing the mixing ratio of a block copolymer carrier, and the administration frequency can be effectively reduced. Besides, the invention further discloses a preparation method of the HER-2 humanized monoclonal antibody long-acting sustained-release preparation, and the method is simple in condition and high in practicability and has good market application potential.

The invention belongs to the technical field of medicines for preventing and treating cardiotoxicity, and particularly relates to application of breviscapine as a chemotherapeutic medicine for preventing and treating cardiotoxicity. According to the defect of the existing listed product-dexrazolidone, the breviscapine shows the characteristics and advantages of the breviscapine in prevention and treatment application in the aspects of cardiotoxicity protection of anthracycline chemotherapeutics and the like, and meanwhile, the breviscapine is low in raw material cost, good in safety basis and suitable for industrial production. The compound can be used as an active component or a medicine composition component for myocardial protection of anthracycline chemotherapeutics, the cardiotoxicity caused by the chemotherapeutics is reduced, and the life quality and the treatment prognosis of tumor patients are improved.

The invention discloses an anthraquinonotriazole antibiotic nucleoside analog, a synthetic method and application of the anthraquinonotriazole antibiotic nucleoside analog in the preparation of an antineoplastic or antiviral drug, and belongs to the field of chemical and medical technologies. According to the key points of the technical scheme, the structural formula of the anthraquinonotriazole antibiotic nucleoside analog is as shown in the specification. The invention also specifically discloses a synthetic method of the anthraquinonotriazole antibiotic nucleoside analog and application ofthe anthraquinonotriazole antibiotic nucleoside analog in the preparation of an antineoplastic or / and antiviral drug. A series of anthraquinonotriazole antibiotic nucleoside analogs with novel structure and bioactivity are prepared in the invention. It is found through biological activity tests that the compounds have good antineoplastic and antiviral activity and can be used for preparation of anantineoplastic or antiviral drug so as to furthermore effectively overcome toxic and side effect such as cardiotoxicity, drug resistance and the like generated by the current long-term use of anthracene nucleus antibiotic drugs.